SAGE1: A Protein Targeted for Drug Development and Biomarker Research

Target Name: SAGE1

NCBI ID: G55511

SAGE1

SAGE1: A Protein Targeted for Drug Development and Biomarker Research

SAGE1 (OTTHUMP00000024088) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the SAGE family of proteins, which are known for their role in cell signaling and inflammation. SAGE1 has been identified as a potential drug target and is the focus of research at the SAGE Research Institute, a non-profit organization dedicated to the advancement of science and technology.

SAGE1 was first identified in the late 1990s by researchers at the University of California, San Diego. They demonstrated that SAGE1 was expressed in a variety of tissues and that it was involved in the regulation of cellular signaling pathways. Since then, researchers have continued to study SAGE1 and its role in various physiological processes.

One of the key features of SAGE1 is its ability to interact with other proteins. This interaction is known as SAGE1-mediated signaling, and it is a critical component of many cellular signaling pathways. SAGE1 can interact with a variety of protein partners, including enzymes that regulate signaling pathways such as tyrosine kinase. These interactions allow SAGE1 to regulate cellular signaling and to play a role in the development of various diseases.

In addition to its role in cell signaling, SAGE1 is also a potential biomarker for a variety of diseases. For example, SAGE1 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, SAGE1 has been linked to the development of cardiovascular disease and other conditions.

SAGE Research Institute is a non-profit organization that is dedicated to the advancement of science and technology. The organization was founded by Dr. David Sinclair, a renowned biologist and professor at Harvard Medical School, and is based in Woburn, Massachusetts. The SAGE Research Institute is comprised of a team of scientists and engineers who are dedicated to solving complex problems in biology and to advancing the frontiers of science.

The SAGE Research Institute has made significant progress in the study of SAGE1 and its role in various diseases. The organization has identified a number of potential drug targets for SAGE1 and is working to develop compounds that can inhibit its activity. These compounds are being tested in a variety of cellular and animal models to determine their effectiveness in treating various diseases.

In addition to its potential as a drug target, SAGE1 is also being studied as a potential biomarker. Researchers have used a variety of techniques to demonstrate that SAGE1 is involved in the development of various diseases, including neurodegenerative diseases, cardiovascular disease, and cancer. These studies are providing new insights into the role of SAGE1 in disease and are helping to advance the field of pharmacology.

Overall, SAGE1 is a protein that is of great interest to researchers because of its ability to interact with other proteins and its potential as a drug target and biomarker. The SAGE Research Institute is dedicated to advancing the study of SAGE1 and its role in various diseases, and we are confident that the organization will continue to make significant progress in the years to come.

Protein Name: Sarcoma Antigen 1

The "SAGE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SAGE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets